Publication | Open Access

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

HypertensionUrologyRenal FunctionCardiovascular DiseasePhase Iii TrialsPhysiologyRenal PathophysiologyMedicineRenal PharmacologyNephrologyBlood PressureAnesthesiology